Author Archives: Iqra Mumal, MSc

Chemical Modifications on Potential Therapeutic Molecules May Increase Effectiveness in FA Treatment, Study Shows

Researchers modified two new classes of drugs, known as duplex RNAs and antisense oligonucleotides, targeted against the Frataxin (FXN) gene, which had a therapeutic effect in cells from patients with Friedreich’s ataxia. The study titled, “Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat,” was…

Friedreich’s Ataxia Patients Have Personality and Minor Cognitive Challenges, Study Suggests

Friedreich’s ataxia patients have a specific personality and neuropsychological profile that is characterized by very mild cognitive impairment, a new study shows. The study, “Personality and Neuropsychological Profiles in Friedreich Ataxia,” was published in the journal The Cerebellum. People with Friedreich’s ataxia (FA) have lesions found primarily…

Symptoms of FA Largely Reversed in New Mouse Model, Study Shows

UCLA scientists have found that many early symptoms of Friedreich’s ataxia (FA) can be reversed, according to research they conducted in a new mouse model of the disease. Their study, titled “Inducible and reversible phenotypes in a novel mouse model of Friedreich’s Ataxia,” was published in the journal…

Activating Nrf2 Protein Might Prevent Nerve Cell Degeneration in Friedreich’s Ataxia, Study Finds

Activating a protein known as Nrf2 might prevent the nerve cell disintegration that is a hallmark of Friedreich’s ataxia, a study indicates. The research, published in the International Journal of Molecular Sciences, involved cells grown in a lab. Its title is “Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic…